Abbott’s disclosed capital expenditure program for 2017–2019 “was principally for upgrading and expanding manufacturing and research and development facilities and equipment in various segments, investments in information technology, and laboratory instruments placed with customers,” reflecting deliberate resource allocation to enhance its IT infrastructure and data-driven operations. In its core laboratory diagnostics business, Abbott is commercializing “informatics solutions to help optimize diagnostics laboratory performance and automation solutions to increase efficiency in laboratories,” underscoring its focus on process automation, information management and connectivity. Within the medical devices segment, research and development priorities include “continued enhancements to Abbott’s left ventricular assist systems and pulmonary artery heart failure system, including enhanced connectivity, user-interfaces and remote patient monitoring,” as well as next-generation diagnostic, mapping, visualization and monitoring technologies in electrophysiology and digital enhancements to its continuous glucose monitoring platform, demonstrating deployment of IT-enabled capabilities to support clinical workflows and real-time data exchange. Moreover, working capital management leverages customer inventory management data to “make reliable estimates of inventory in the retail distribution channel,” illustrating the integration of information systems and data analytics to improve forecasting, decision-making speed and operational efficiency across the enterprise.